on Evotec AG (NASDAQ:EVTCY)
Evotec SE Annual General Meeting 2025 Highlights
Evotec SE recently held its Annual General Meeting (AGM) for 2025, where a significant majority of shareholders approved the proposals presented by the Company’s Management. Centered on "Pioneering Drug Discovery," CEO Dr. Christian Wojczewski provided insights into Evotec's strategic and scientific direction.
The meeting saw 46.45% of the registered share capital being represented. Key decisions included the discharge of current and former Board members from liability for the 2024 fiscal year, and approval of the Remuneration Report 2024. Amendments to allow virtual meetings and modifications to the Share Performance Plan 2022 were also endorsed.
Additionally, new Management Board members Aurélie Dalbiez and Paul Hitchin were introduced. BDO AG was confirmed as auditors for 2025. Full details and voting outcomes can be accessed on Evotec’s investor relations website.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Evotec AG news